Role of minimal residual disease evaluation in leukemia therapy

Current Hematologic Malignancy Reports

Volumn 3, Issue 3, 2008, Pages 155-160

  Campana, Dario ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MARKER; LYMPHOCYTE ANTIGEN RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; CANCER RISK; CANCER THERAPY; CLINICAL EVALUATION; DIAGNOSTIC PROCEDURE; DISEASE MARKER; FLOW CYTOMETRY; HUMAN; IMMUNOPHENOTYPING; LEUKEMIA; LEUKEMIA CELL; METHODOLOGY; MINIMAL RESIDUAL DISEASE; POLYMERASE CHAIN REACTION; PROGNOSIS; RELAPSE; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE;

FLOW CYTOMETRY; GENES, T-CELL RECEPTOR; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, MYELOID, ACUTE; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; RECURRENCE;

EID: 47549117770     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-008-0022-x     Document Type: Article

References (50)

1. Pui CH, Evans WE: Treatment of acute lymphoblastic leukemia. N Engl J Med 2006, 354:166-178.
2. Evans WE, Relling MV: Moving towards individualized medicine with pharmacogenomics. Nature 2004, 429:464-468.
3. Armstrong SA, Look AT: Molecular genetics of acute lymphoblastic leukemia.J Clin Oncol 2005, 23:6306-6315.
4. Flotho C, Coustan-Smith E, Pei D, et al.: Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2. Blood 2006, 108:1050-1057.
5. Flotho C, Coustan-Smith E, Pei D, et al.: A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia. Blood 2007, 110:1271-1277.
6. Iwamoto S, Mihara K, Downing JR., et al.: Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest 2007, 117:1049-1057.
7. Sandlund JT, Harrison PL, Rivera G, et al.: Persistence of lymphoblasts in bone marrow on day 15 and days 22 to 25 of remission induction predicts a dismal treatment outcome in children with acute lymphoblastic leukemia. Blood 2002, 100:43-47.
8. Kern W, Haferlach T, Schoch C, et al.: Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. Blood 2003, 101:64-70.
9. Szczepanski T, Orfao A, van der Velden VH, et al.: Minimal residual disease in leukaemia patients. Lancet Oncol 2001, 2:409-417.
10. Campana D: Determination of minimal residual disease in leukemia patients. Br J Haematol 2003, 121:823-838.
11. Coustan-Smith E, Sancho J, Hancock ML, et al.: Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 2000, 96:2691-2696.
12. Coustan-Smith E, Ribeiro RC, Rubnitz JE, et al.: Clinical significance of residual disease during treatment in childhood acute myeloid leukemia. Br J Haematol 2003, 123:243-252.
13. Pongers-Willemse MJ, Seriu T, Stolz F, et al.: Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets. Leukemia 1999, 13:110-118.
14. van der Velden V, Hochhaus A, Cazzaniga G, et al.: Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia 2003, 17:1013-1034.
15. Boeckx N, Willemse MJ, Szczepanski T, et al.: Fusion gene transcripts and Ig/TCR gene rearrangements are complementary but infrequent targets for PCR-based detection of minimal residual disease in acute myeloid leukemia. Leukemia 2002, 16:368-375.
16. van Dongen JJ, Macintyre EA, Gabert JA, et al.: Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999, 13:1901-1928.
17. Gabert J, Beillard E, van der Velden V, et al.: Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 2003, 17:2318-2357.
18. Shih LY, Huang CF, Wu JH, et al.: Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse. Blood 2002, 100:2387-2392.
19. Kottaridis PD, Gale RE, Langabeer SE, et al.: Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. Blood 2002, 100:2393-2398.
20. Ogawa H, Tamaki H, Ikegame K, et al.: The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 2003, 101:1698-704.
21. Cilloni D, Gottardi E, Fava M, et al.: Usefulness of quantitative assessment of the WT1 gene transcript as a marker for minimal residual disease detection. Blood 2003, 102:773-774.
22. Neale GA, Coustan-Smith E, Stow P, et al.: Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia 2004, 18:934-938.
23. Kerst G, Kreyenberg H, Roth C, et al.: Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR. Br J Haematol 2005, 128:774-782.
24. Coustan-Smith E, Ribeiro RC, Stow P, et al.: A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome. Blood 2006, 108:97-102.
25. Coustan-Smith E, Sancho J, Hancock ML, et al.: Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. Blood 2002, 100:2399-2402.
26. van der Velden V, Jacobs DC, Wijkhuijs AJ, et al.: Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL. Leukemia 2002, 16:1432-1436.
27. Brisco MJ, Condon J, Hughes E, et al.: Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction. Lancet 1994, 343:196-200.
28. Cavé H, van der Werff ten Bosch J, Suciu S, et al.: Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer - Childhood Leukemia Cooperative Group. N Engl J Med 1998, 339:591-598.
29. van Dongen JJ, Seriu T, Panzer-Grumayer ER, et al.: Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998, 352:1731-1738.
30. Flohr T, Schrauder A, Cazzaniga G, et al.: Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia 2008, 22:771-782.
31. Zhou J, Goldwasser MA, Li A, et al.: Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01. Blood 2007, 110:1607-1611.
32. Coustan-Smith E, Behm FG, Sanchez J, et al.: Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet 1998, 351:550-554.
33. Coustan-Smith E, Sancho J, Behm FG, et al.: Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood 2002, 100:52-58.
34. Panzer-Grumayer ER, Schneider M, Panzer S, et al.: Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. Blood 2000, 95:790-794.
35. Borowitz MJ, Devidas M, Hunger SP, et al.: Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood 2008 Apr 3 (Epub ahead of print).
36. Pui CH, Campana D, Evans WE: Childhood acute lymphoblastic leukemia - current status and future perspectives. Lancet Oncol 2001, 2:597-607.
37. Biondi A, Valsecchi MG, Seriu T, et al.: Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group. Leukemia 2000, 14:1939-1943.
38. Eckert C, Biondi A, Seeger K, et al.: Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia. Lancet 2001, 358:1239-1241.
39. Coustan-Smith E, Gajjar A, Hijiha N, et al.: Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse. Leukemia 2004, 18:499-504.
40. Krejci O, van der Velden VH, Bader P, et al.: Level of minimal residual disease prior to haematopoietic stem cell transplantation predicts prognosis in paediatric patients with acute lymphoblastic leukaemia: a report of the Pre-BMT MRD Study Group. Bone Marrow Transplant 2003, 32:849-851.
41. Lo-Coco F, Ammatuna E: Front line clinical trials and minimal residual disease monitoring in acute promyelocytic leukemia. Curr Top Microbiol Immunol 2007, 313:145-156.
42. Tobal K, Newton J, Macheta M, et al.: Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse. Blood 2000, 95:815-819.
43. Marcucci G, Caligiuri MA, Dohner H, et al.: Quantification of CBFbeta/MYH11 fusion transcript by real time RT-PCR in patients with INV(16) acute myeloid leukemia. Leukemia 2001, 15:1072-1080.
44. San Miguel JF, Vidriales MB, Lopez-Berges C, et al.: Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood 2001, 98:1746-1751.
45. Venditti A, Maurillo L, Buccisano F, et al.: Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation. Leukemia 2003, 17:2178-2182.
46. Buccisano F, Maurillo L, Gattei V, et al.: The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. Leukemia 2006, 20:1783-1789.
47. Sievers EL, Lange BJ, Alonzo TA, et al.: Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 acute myeloid leukemia patients. Blood 2003, 101:3398-3406.
48. Ribeiro RC, Pui CH: Saving the children - improving childhood cancer treatment in developing countries. N Engl J Med 2005, 352:2158-2160.
49. Chen JS, Coustan-Smith E, Suzuki T, et al.: Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia. Blood 2001, 97:2115-2120.
50. Irish JM, Kotecha N, Nolan GP: Mapping normal and cancer cell signalling networks: towards single-cell proteomics. Nat Rev Cancer 2006, 6:146-155.